Oxurion

Foundation date

30/05/2006

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Oxurion is dedicated to developing and commercializing new pharmacologic ophthalmic treatments that address important unmet clinical needs. By meeting this goal Oxurion intends to help patients around the world with a new or better treatment for their condition.

Upcoming events

Latest news

  • Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

    14 hours ago

  • Indigo Diabetes announces first participant enrolled in the SHINE clinical trial

    Thursday September 29th 2022

  • FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome

    Tuesday September 27th 2022